Dysregulation of the PP2A–integrator–cyclin-dependent kinase 9 (CDK9) axis is commonly observed in various cancers and can arise from genetic alterations or overexpression of inhibitory molecules [15,16,17]. Here, CDK9 is linked to cancer.